Transfection is the process of deliberately introducing foreign genetic material into animal or human cells. Scientists use it to deliver DNA, RNA, or smaller genetic molecules into cells to change how those cells behave, what proteins they produce, or which genes they express. It’s one of the foundational techniques in modern biology, and it underpins everything from basic lab research to COVID-19 mRNA vaccines.
How Transfection Works
Every cell is surrounded by a membrane that acts as a selective barrier, keeping most large molecules out. Genetic material like DNA and RNA can’t simply pass through on its own. Transfection uses chemical, physical, or biological strategies to get past that barrier and deliver the genetic cargo into the cell’s interior, where it can be read and used by the cell’s own machinery.
Once inside, the introduced genetic material instructs the cell to produce specific proteins, silence certain genes, or alter its behavior in targeted ways. The types of material that can be delivered include standard DNA and RNA, as well as smaller regulatory molecules (like siRNA and miRNA) that can switch specific genes off. This flexibility makes transfection useful across a wide range of experiments and therapies.
Transient vs. Stable Transfection
There are two fundamentally different outcomes depending on how the introduced genetic material interacts with the cell, and the distinction matters for how long the effect lasts.
Transient transfection delivers genetic material that stays separate from the cell’s own genome. The cell reads the instructions and produces protein for a short window, typically a few days to two weeks, but the foreign material is gradually lost. When the cell divides, daughter cells don’t inherit it. This approach is ideal for short-term experiments, quick protein production, or situations where you want a temporary effect without permanently altering the cell.
Stable transfection integrates the foreign DNA directly into the cell’s genome. Because it becomes part of the cell’s own genetic code, every future generation of that cell carries and expresses the new gene. This is how researchers create permanent cell lines that continuously produce a desired protein. The tradeoff is that stable transfection takes longer to establish and requires a selection step to identify the cells that successfully incorporated the new DNA.
Chemical Transfection Methods
Chemical methods are the most widely used approach in research labs because they’re relatively simple and don’t require specialized equipment.
Lipofection uses tiny fat-based particles (lipid carriers) that wrap around the genetic material. Because cell membranes are also made of lipids, these packages can fuse with the membrane and release their cargo inside. It’s the same basic principle behind the lipid nanoparticles used in mRNA vaccines.
Calcium phosphate co-precipitation is one of the oldest and cheapest methods. DNA is mixed with calcium chloride and a buffered salt solution, forming a fine mineral precipitate that settles onto cells growing on a dish. The cells take up the precipitate along with the attached DNA. It works well for certain cell types but can be finicky, since the size and quality of the precipitate affect results.
Polymer-based transfection uses positively charged synthetic molecules that bind to negatively charged DNA, condensing it into compact particles that cells absorb. Polyethylenimine (PEI) is the most common example and is widely used for large-scale protein production because it’s effective and inexpensive.
Physical Transfection Methods
Electroporation applies brief electrical pulses to cells, which temporarily open tiny pores in the cell membrane. Genetic material in the surrounding solution flows through these pores before they reseal. It’s particularly useful for cell types that resist chemical methods, and it’s a key technique in manufacturing CAR-T cell therapies, where a patient’s immune cells are engineered to fight cancer.
Microinjection uses a microscopic needle to physically inject genetic material into a single cell. It’s precise but slow, making it practical only when you need to transfect a small number of cells with high certainty, such as in embryo engineering.
Biolistics (sometimes called the gene gun) coats tiny metal particles with DNA and fires them into cells at high speed. Originally developed for plant cells, which have tough outer walls that resist other methods, it’s occasionally used for animal cells as well.
What Affects Transfection Efficiency
Getting genetic material into cells sounds straightforward, but the percentage of cells that actually take it up and express it (the transfection efficiency) varies dramatically depending on conditions. Several factors matter.
Cell density at the time of transfection is one of the most important variables. Cells need to be actively dividing for good DNA uptake. In optimization studies, researchers have found that lower seeding densities (around 25,000 cells per square centimeter) often outperform higher densities because more cells are in their active growth phase. Overly crowded or overly sparse cultures both reduce efficiency.
The ratio of transfection reagent to DNA also requires careful tuning. Too little reagent and the DNA isn’t packaged efficiently; too much and toxicity increases. For PEI-based methods, optimal ratios typically fall around 6 to 7 parts reagent per part DNA by weight, though this varies by cell type and reagent formulation.
Cell type is often the biggest wildcard. Some cell lines transfect easily with nearly any method, while primary cells (taken directly from tissue rather than grown in a lab for generations) and immune cells can be extremely resistant to chemical methods, often requiring electroporation instead.
The Toxicity Tradeoff
Most transfection reagents are inherently somewhat toxic to cells because they carry a positive charge or interact aggressively with cell membranes. This creates a persistent challenge: conditions that push more genetic material into cells also tend to kill more of them. As one research group described it, scientists often face a choice between high efficiency with devastating toxicity, or low toxicity with minimal effect.
This matters more than it might seem. If a transfection reagent kills a large fraction of cells, the surviving population may not be representative of the original. The reagent itself becomes a variable in the experiment, potentially skewing results. In practical terms, researchers aim for conditions where at least 90% of cells survive the process, though achieving both high efficiency and high viability at the same time often requires careful optimization or newer biodegradable reagent formulations that break down into nontoxic fragments once inside the cell.
Protein Expression Timelines
After transient transfection, cells don’t immediately produce protein. There’s a lag while the cell’s machinery reads the new genetic instructions, produces messenger RNA, and translates it into protein. For most experiments, conditioned medium (the liquid surrounding the cells, now containing secreted protein) is collected 4 to 7 days after transfection.
The production window depends on cell health and culture conditions. In standard roller bottle cultures, cells may produce protein for about 7 days before declining. In optimized culture systems with better oxygen exchange, production can extend to 10 or even 14 days. Beyond that, protein degradation and cell death start to offset any additional yield, so most researchers harvest within that window.
Real-World Applications
Transfection moved well beyond the research bench years ago. It now plays a central role in several areas of medicine.
The COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna are essentially transfection delivered to the body. Lipid nanoparticles carry mRNA into your cells, which then temporarily produce the spike protein and trigger an immune response. The same lipid nanoparticle technology is being adapted for other vaccines and therapies.
CAR-T cell therapy, used to treat certain blood cancers, relies on transfecting a patient’s own immune cells with new genetic instructions that enable them to recognize and attack tumor cells. Companies use electroporation and gene-editing tools like CRISPR to engineer these cells before infusing them back into the patient.
RNA-based drugs also depend on transfection principles. Onpattro, approved for a rare hereditary nerve disease, uses lipid nanoparticles to deliver small interfering RNA that silences a disease-causing gene. Treatments for spinal muscular atrophy and Duchenne muscular dystrophy use related strategies to correct or compensate for genetic defects at the RNA level.
In research settings, transfection remains the workhorse technique for studying gene function, producing proteins for drug development, and testing gene-editing systems before they’re used in patients. Nearly every gene therapy or genetic medicine in development today traces its foundation back to this process of getting foreign genetic material past a cell membrane.